Ferguson Wellman Capital Management Inc. decreased its position in Pfizer Inc. (NYSE:PFE) by 1.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 128,375 shares of the biopharmaceutical company’s stock after selling 1,815 shares during the period. Ferguson Wellman Capital Management Inc.’s holdings in Pfizer were worth $4,712,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. increased its holdings in Pfizer by 0.8% during the 2nd quarter. BlackRock Inc. now owns 427,534,404 shares of the biopharmaceutical company’s stock worth $13,980,372,000 after purchasing an additional 3,464,207 shares during the period. State Street Corp increased its stake in shares of Pfizer by 0.3% during the first quarter. State Street Corp now owns 292,621,398 shares of the biopharmaceutical company’s stock valued at $9,551,162,000 after buying an additional 830,299 shares during the period. Capital World Investors lifted its stake in Pfizer by 19.1% in the first quarter. Capital World Investors now owns 224,808,113 shares of the biopharmaceutical company’s stock worth $7,337,737,000 after acquiring an additional 36,092,723 shares during the period. Bank of New York Mellon Corp grew its holdings in Pfizer by 1.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 57,111,863 shares of the biopharmaceutical company’s stock worth $1,867,559,000 after acquiring an additional 1,024,264 shares in the last quarter. Finally, Sanders Capital LLC increased its position in Pfizer by 5.0% during the 2nd quarter. Sanders Capital LLC now owns 28,282,011 shares of the biopharmaceutical company’s stock valued at $1,046,595,000 after purchasing an additional 1,349,012 shares during the period. Hedge funds and other institutional investors own 69.08% of the company’s stock.
In other news, Director Ronald E. Blaylock bought 13,000 shares of Pfizer stock in a transaction that occurred on Thursday, August 6th. The stock was bought at an average price of $38.55 per share, for a total transaction of $501,150.00. Following the purchase, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $154,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.08% of the stock is owned by corporate insiders.
Shares of PFE stock opened at $37.95 on Friday. Pfizer Inc. has a fifty-two week low of $27.88 and a fifty-two week high of $40.97. The firm has a market capitalization of $210.88 billion, a price-to-earnings ratio of 15.06, a PEG ratio of 2.91 and a beta of 0.67. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.42. The stock’s 50-day simple moving average is $36.59 and its 200-day simple moving average is $36.32.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.14. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The company had revenue of $11.80 billion during the quarter, compared to analysts’ expectations of $11.55 billion. During the same period last year, the business earned $0.80 EPS. Pfizer’s revenue for the quarter was down 11.0% on a year-over-year basis. As a group, equities analysts forecast that Pfizer Inc. will post 2.89 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, November 6th will be issued a dividend of $0.38 per share. This represents a $1.52 dividend on an annualized basis and a dividend yield of 4.01%. The ex-dividend date is Thursday, November 5th. Pfizer’s dividend payout ratio (DPR) is presently 51.53%.
A number of equities analysts have recently issued reports on the stock. Atlantic Securities downgraded shares of Pfizer from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $44.00 to $39.00 in a research note on Monday, October 12th. Morgan Stanley increased their target price on Pfizer from $36.00 to $42.00 and gave the company an “equal weight” rating in a research report on Thursday, July 30th. Mizuho reissued a “buy” rating and issued a $43.00 price target on shares of Pfizer in a research report on Tuesday, September 15th. UBS Group upped their price objective on Pfizer from $37.00 to $39.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 29th. Finally, Royal Bank of Canada set a $43.00 target price on Pfizer and gave the company a “buy” rating in a research note on Friday. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $39.64.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Recommended Story: What do I need to know about analyst ratings?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.